News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Visiomed Group Limited (VSG) Begins Clinical Evaluation Trials Of MicroEYE(Tm)

10/19/2005 5:09:22 PM

Australia, Monday June 27 2005: Biomedical devices developer, Visiomed Group Ltd (ASX:VSG) and ophthalmic surgical laser group, CustomVis (AIM:CUS), announced today that their ophthalmic imaging system, microEYE, has begun a clinical evaluation trial.

The microEYE is a hand-held camera system capable of imaging different regions of the eye using one device, instead of using a number of devices. The device also provides digital capture-storage-retrieval images to enable immediate diagnosis and continued monitoring.

The microEYE is targeted for use in the diagnosis and monitoring of eye pathologies associated with the posterior segment, such as diabetic retinopathy, glaucoma and macular degeneration as well as pathologies associated with the anterior segment such as trachoma and cataracts.

The clinical evaluation of the microEYE will be undertaken by between 20 to 25 optometrists and ophthalmologists and will take place over the next months.

"This is an exciting step towards the commercialisation of the microEYE. We have selectively chosen optometrists and ophthalmologists that will hopefully become strong advocates of the technology," said Mr William Dolphin, CEO of Visiomed.

A prototype microEYE System was recently displayed at the joint meeting of the American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators (ASCRS/ASOA) in Washington, DC. Some of the competitive advantages of the microEYE will include pricing, system portability, multi-functionality for disease screening, ease-of-use, archiving and telemedicine facilities.

In excess of 160 million people suffer from disabling visual problems worldwide, according to the World Heath Organization figures, a figure that is expected to double by the year 2030. Early diagnosis and continued monitoring of eye diseases such as cataract, glaucoma, macular degeneration and diabetic retinopathy could prevent the onset of blindness in most cases.

About Visiomed Group Ltd

Visiomed ( develops and commercialises innovative medical devices. Apart from the Funhaler®, Visiomed also has the exclusive world wide licences for computer-based smart systems for the imaging and diagnosis of diseases other than dermatological conditions. The company is utilising its intellectual property to develop the microEYE™ imaging system as an aid in the screening and diagnosis of eye diseases such as cataract, glaucoma, trachoma, macular degeneration and diabetic retinopathy.

About CustomVis

CustomVis develops, manufactures and commercialises solid state laser optical equipment for use within the laser vision correction industry. The production Quality System is certified to ISO 13485 for Medical Devices. The company has proprietary intellectual property and patents covering its laser optical systems and eye tracking technologies. CustomVis is listed on the London Alternative Investment Market (London AIM code CUS.)

For further information, please contact Visiomed’s CEO Dr William Dolphin on (08) 9321 2712.

For media enquiries please contact Rebecca Wilson (Christie), Buchan (02) 9237 2800 or 0417 382 391,

Read at

comments powered by Disqus